Project Grant R01AI200748
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Scripps Research Institute a Project Grant totaling $1,285,304 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and evaluate an enhanced HIV vaccine regimen capable of producing durable broadly neutralizing antibody (BNAB) responses. The research, which commenced August 1, 2025, and extends through July 31, 2030, leverages a novel six-shot germline-targeting...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the Scripps Research Institute a $910,905 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective July 1, 2025, with completion targeted for February 12, 2026. This award supports research advancing HIV vaccine development through the application of lipid nanodisc platform technology. The project will develop and characterize engineered transmembrane...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3.56 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to J. David Gladstone Institutes on September 26, 2025, to support research through August 31, 2029. This grant funds the development and validation of a hybrid messenger RNA (mRNA) vaccine technology designed to elicit broadly neutralizing antibodies (bnAbs) against HIV-1. The primary...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Pennsylvania a $891,410 Project Grant on August 14, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and test a personalized therapeutic HIV vaccine strategy. The research, scheduled for completion by July 31, 2030, focuses on designing individualized messenger RNA (mRNA)-lipid nanoparticle (LNP) delivered envelope immunogens to boost...
- Federal Grant Award Summary The Scripps Research Institute received a $511,531 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 13, 2026, through January 31, 2031. The primary deliverable is the development and characterization of HIV envelope (ENV) glycoprotein vaccine candidates utilizing a lipid nanodisc platform. The research addresses a critical gap in HIV vaccine...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $121,182.00 to the University of California, San Diego under the Allergy and Infectious Diseases Research program (CFDA 93.855) on December 5, 2025, with a completion date of February 3, 2028. This Project Grant supports fundamental research investigating how vaccine formulations influence germinal center (GC) dynamics—the specialized immune microenvironments where B cells develop broadly...
- Federal Project Grant Award Summary The Scripps Research Institute received a $1,379,954 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 21, 2025, with completion targeted for July 31, 2030. The award supports systematic research to engineer durable immunity through optimization of Human Immunodeficiency Virus (HIV) vaccine parameters designed to drive...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital a Project Grant of $889,519 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period April 1, 2026 through March 31, 2031. This award supports research and development of a multi-biologic, adeno-associated virus (AAV)-deliverable HIV-1 functional cure combining broadly neutralizing antibodies (BNAbs) and ECD4-IG, a potency and half-life...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Scripps Research Institute a $3.02 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) beginning August 8, 2025, with a completion date of July 31, 2029. This award supports the design and development of single-shot sequential immunization regimens for HIV using atomic layer deposition (ALD) technology. The research builds upon preclinical successes...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $368,750 to the Veterans Medical Research Foundation of San Diego under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 10, 2025, for a project period extending through June 30, 2030. This Project Grant funds biomedical research investigating the mechanisms by which HIV-1 and HIV-2 antagonize BST2/tetherin, an interferon-stimulated gene with potent antiviral...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $887,239 Project Grant to The Wistar Institute of Anatomy and Biology for research on redirecting antibody epitope specificity with HIV-1 envelope-based immunization. The five-year award, effective May 1, 2026 through April 30, 2031, supports investigator-initiated research under CFDA 93.855 (Allergy and Infectious Diseases Research). The research addresses a critical barrier to HIV-1 vaccine development: the immunodominant but non-neutralizing antibody responses directed toward the gp41 base of the envelope glycoprotein when using soluble envelope trimers as immunogens. This off-target immune response has derailed multiple clinical vaccine trials despite numerous attempts to occlude the envelope base. The project will investigate the phenomenon of antibody epitope switching, examining how broadly neutralizing antibody (BNAb) precursor lineages can be derailed from maturation and how non-neutralizing antibodies can be redirected to mature into functional BNAbs targeting neutralization-sensitive epitopes. Specifically, the research will characterize "derailed" and "rescued" antibodies to understand on-target to off-target epitope switching mechanisms, informing vaccine design strategies that prevent antibody switching toward the envelope base, while simultaneously investigating off-target to on-target switching to develop vaccine approaches that recycle non-neutralizing responses into effective broadly neutralizing antibody responses.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $887.2k | 5/4/26 |